Cargando…

Immunogenicity and Safety of a Booster Dose of Live Attenuated Varicella Vaccine, and Immune Persistence of a Primary Dose for Children Aged 2 to 6 Years

Aim: To evaluate the immunogenicity and safety of a booster dose of live attenuated varicella vaccine (VarV) manufactured by Sinovac (Dalian) Vaccine Technology Co. Ltd., and the immune persistence of a primary dose in 2- to 6-year-old children. Methods: A phase IV, open-label study was conducted in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yukai, Wang, Lei, Wang, Yanxia, Zhang, Wei, Jia, Ningning, Xie, Zhiqiang, Huang, Lili, You, Wangyang, Lu, Weifeng, Li, Erwei, Gao, Feilong, Hu, Yuansheng, Meng, Fanhong, Xia, Shengli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146173/ https://www.ncbi.nlm.nih.gov/pubmed/35632416 http://dx.doi.org/10.3390/vaccines10050660

Ejemplares similares

Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents
por: Wang, Lei, et al.
Publicado: (2022)

Safety and immunogenicity of booster dose in patients with chronic liver disease
por: Cossiga, V., et al.
Publicado: (2023)

636. Immunogenicity, Safety and Tolerability of a Booster Dose of Clostridium difficile Vaccine and 4 Year Antibody Persistence
por: Remich, Shon A, et al.
Publicado: (2020)

Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults
por: Zhang, Yuntao, et al.
Publicado: (2022)

Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine
por: Cao, Yunlong, et al.
Publicado: (2021)

Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies
por: Vargas, Leonardo, et al.
Publicado: (2022)

Humoral and cellular immunogenicity of COVID-19 booster dose vaccination in inflammatory arthritis patients
por: Wroński, Jakub, et al.
Publicado: (2022)

Effect of Routine Varicella Immunization on the Epidemiology and Immunogenicity of Varicella and Shingles
por: Otani, Naruhito, et al.
Publicado: (2022)

Immunogenicity of Simulated PCECV Postexposure Booster Doses 1, 3, and 5 Years after 2-Dose and 3-Dose Primary Rabies Vaccination in Schoolchildren
por: Kamoltham, Thavatchai, et al.
Publicado: (2011)

Immunogenicity Is Not Improved by Increased Antigen Dose or Booster Dosing of Seasonal Influenza Vaccine in a Randomized Trial of HIV Infected Adults
por: Cooper, Curtis, et al.
Publicado: (2011)

Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose
por: Capeding, Maria Rosario, et al.
Publicado: (2022)

Long-term immunogenicity of hepatitis B vaccine and impact of a booster dose on health care
por: Bijani, Behzad, et al.
Publicado: (2019)

Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial
por: Omma, Ahmet, et al.
Publicado: (2022)

Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis
por: Zhan, Haoting, et al.
Publicado: (2023)

Safety and Immunogenicity of Anti-SARS-CoV-2 Booster Dose in Patients with Chronic Liver Disease
por: Cossiga, Valentina, et al.
Publicado: (2023)

Evaluation of immunogenicity, safety and breakthrough following administration of live attenuated varicella vaccine in two doses three months apart regimen in Indian children
por: Mitra, Monjori, et al.
Publicado: (2020)

Safety and immunogenicity of single dose live attenuated varicella vaccine (VR 795 Oka strain) in healthy Indian children: A randomized controlled study
por: Mitra, Monjori, et al.
Publicado: (2015)

Immunogenicity of ChAdOx1 (Covishield) Booster Dose in Healthcare Providers: A Pre-Post Study
por: Meher, Trupti, et al.
Publicado: (2023)

Booster Doses and Prioritizing Lives Saved
por: Patel, Minal K.
Publicado: (2021)

Effects of Varicella Vaccine Time of First Dose and Coverage of Second Dose — Beijing and Ningbo, China, 2012–2018
por: Chen, Yuewei, et al.
Publicado: (2020)

Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai Children
por: Watanaveeradej, Veerachai, et al.
Publicado: (2016)

Factors Influencing Persistence of Diphtheria Immunity and Immune Response to a Booster Dose in Healthy Slovak Adults
por: Petráš, Marek, et al.
Publicado: (2019)

COVID-19 vaccine equity and booster doses
por: The Lancet Infectious Diseases
Publicado: (2021)

COVID vaccine booster doses for omicron variants
por: Burki, Talha
Publicado: (2022)

Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer
por: Han, Shanshan, et al.
Publicado: (2023)

1612P Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy
por: Guven, D.C.C., et al.
Publicado: (2022)

Immunogenicity and Safety of the Third Booster Dose with mRNA-1273 COVID-19 Vaccine after Receiving Two Doses of Inactivated or Viral Vector COVID-19 Vaccine
por: Tangsathapornpong, Auchara, et al.
Publicado: (2023)

Safety and immunogenicity of a skin- and neuro-attenuated live vaccine for varicella: a randomized, double-blind, controlled, dose-escalation and age de-escalation phase 1 clinical trial
por: Mo, Zhao-Jun, et al.
Publicado: (2023)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

Effect of Earlier Vaccination and a Two-Dose Varicella Vaccine Schedule on Varicella Incidence — Beijing Municipality, 2007–2018
por: Zhao, Dan, et al.
Publicado: (2021)

2725. Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Adolescents and Adults
por: Hedrick, James, et al.
Publicado: (2019)

Immunogenicity and Reactogenicity of the Booster Dose of COVID-19 Vaccines and Related Factors: A Panel Study from the General Population in Serbia
por: Stosic, Maja, et al.
Publicado: (2022)

A third (booster) dose of the inactivated SARS-CoV-2 vaccine elicits immunogenicity and T follicular helper cell responses in people living with HIV
por: Lv, Zhengchao, et al.
Publicado: (2023)

Immuno-persistence of the different primary polio vaccine schedules and immunogenicity of the booster dose by sabin inactivated or bivalent oral poliovirus vaccine in children aged 4 years: an open-label, randomised, controlled phase 4 trial in China
por: Tang, Xuewen, et al.
Publicado: (2023)

Changes of immunogenic profiles between a single dose and one booster influenza vaccination in hemodialysis patients – an 18-week, open-label trial
por: Chang, Yu-Tzu, et al.
Publicado: (2016)

1084 Persistence of Meningococcal Antibodies and Response to a Booster Dose after a Two-dose Vaccination Series with Investigational MenABCWY Vaccine Formulations in Adolescents
por: Saez-Llorens, Xavier, et al.
Publicado: (2014)

Safety of seven COVID-19 vaccine booster doses
Publicado: (2021)

Interim statement on covid-19 vaccine booster doses
Publicado: (2021)

Myopericarditis After COVID-19 Booster Dose Vaccination
por: Sharff, Katie A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s27osf0n7hvjtauurf4afnc8em